XenoPort, Inc. - We are a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. In April 2011, the FDA approved our first product, Horizant™ (gabapentin enacarbil) Extended-Release Tablets. Our collaborator, GlaxoSmithKline (GSK), is currently promoting Horizant in the United States. We are also developing gabapentin enacarbil with Astellas Pharma Inc. in Japan and five Asian countries. XenoPort’s product candidates are being developed for the potential treatment of neuropathic pain, spasticity and Parkinson’s disease.

For more information, please click here

Wed, 18 Jan 2012 Astellas and XenoPort Announce Approval of Regnite(R) Tablets for Restless Legs Syndrome in Japan Wed, 04 Jan 2012 XenoPort to Present at the 30th Annual J.P. Morgan Healthcare Conference   XenoPort, Inc. at JPMorgan Global Healthcare Conference Thursday, January 12, 2012 1:30 p.m. PT XenoPort Inc at Piper Jaffray Health Care Conference Wednesday, November 30, 2011 10:30 a.m. ET

XenoPort is focused on development of product candidates for the potential treatment of central nervous system (CNS) disorders, including neuropathic pain, spasticity and Parkinson’s disease. Explore the XenoPort Pipeline >